The Complete Guide to Psychedelic Therapy Options in 2026
Ibogaine, ketamine, psilocybin, MDMA, ayahuasca, 5-MeO-DMT — the options are growing fast. Here's exactly how each works, what it treats, and how to choose.
What psychedelic therapy options exist in 2026?
Six with real evidence: ketamine and esketamine (legal in the US today), psilocybin (state programs and trials), MDMA-assisted therapy (phase-3 data, limited access), ibogaine (licensed clinics abroad, strongest for opioid dependence), 5-MeO-DMT (retreats abroad) and ayahuasca (ceremonial settings). Which one fits depends on the condition, not the hype.
Five years ago, psychedelic therapy was on the fringes of medicine — interesting to researchers, inaccessible to patients. In 2026, the landscape looks different.
Ketamine is in 1,000+ US clinics. Psilocybin is legal in Oregon and Colorado. MDMA achieved 67% PTSD remission in Phase 3 trials. Ibogaine is being studied at Stanford. Australia became the first country to approve MDMA-assisted therapy. The FDA has given psilocybin and MDMA Breakthrough Therapy designation.
If you’re suffering from treatment-resistant depression, PTSD, addiction, or severe anxiety — and nothing has worked — you now have more legitimate options than at any point in modern history.
The Six Major Psychedelic Medicines
1. Ketamine — The Legal US Option
Best for: Treatment-resistant depression, suicidal ideation, PTSD, anxiety, opioid withdrawal Legal in US? Yes — fully legal in all 50 states (IV off-label; Spravato FDA-approved) Cost: $2,400–$4,800 for a full course Sessions: 6 infusions over 2–3 weeks
For a full picture of what to expect, see a complete breakdown of program costs.
Ketamine is your fastest, most accessible entry point if you’re in the US. It works quickly, is medically well-understood, and has a safety profile suitable for outpatient clinical settings. It’s not the deepest psychedelic experience — but it works, it’s legal, and it’s here.
→ Full Guide: Ketamine Therapy
2. Psilocybin — Breakthrough Depression Treatment
Best for: Depression (including treatment-resistant), smoking cessation, alcohol use disorder, existential distress Legal in US? Oregon + Colorado; internationally in Jamaica, Netherlands, Costa Rica Cost: $1,500–$5,000 per session Sessions: 1–3
The Johns Hopkins data demands attention: two psilocybin sessions produced remission in 54% of treatment-resistant depression patients at four weeks. For context, “treatment-resistant” means at least two antidepressants already failed. One to two sessions outperformed those medications in a fraction of the time.
→ Full Guide: Psilocybin Therapy
3. Ibogaine — The Addiction Interrupter
Best for: Opioid addiction, stimulant addiction, kratom dependence Legal in US? No — requires travel to Mexico, Jamaica, Costa Rica, etc. Cost: $5,000–$15,000 Sessions: 1 (comprehensive 12–24 hour session)
Nothing in the psychiatric pharmacopeia does what ibogaine does. A single session can eliminate opioid withdrawal and reset the brain’s addiction circuitry simultaneously. The cardiac risks require medical screening, and travel is required — but for opioid-dependent patients who’ve exhausted other options, ibogaine represents a genuinely new category of treatment.
If you or someone close to you needs help right now, SAMHSA’s national helpline is free, confidential and staffed 24/7 on 1-800-662-HELP.
→ Full Guide: Ibogaine Safety | Find a Clinic
4. MDMA — PTSD Breakthrough
Best for: Chronic PTSD from any cause Legal in US? No (clinical trials and expanded access only); approved in Australia Cost: Varies (trials often free; Australia program ~$2,500–$5,000) Sessions: 2–3 MDMA sessions within 15-session therapy program
MAPS’s Phase 3 data is hard to overstate: 67% of PTSD patients no longer met diagnostic criteria at 18-month follow-up. For combat veterans, survivors of sexual trauma, and childhood abuse survivors who’ve tried conventional therapy and medication — MDMA may represent a genuine path to remission.
5. Ayahuasca — Deep Healing in Ceremony
Best for: Depression, trauma, alcohol addiction, meaning-seeking Legal in US? Some religious programs (UDV, Santo Daime); otherwise international Cost: $1,500–$6,000 (retreat format) Sessions: 2–5 ceremonies over a retreat
Ayahuasca is ceremony medicine — deeply embedded in tradition, typically practiced in group format, combining DMT with MAO inhibitors in the vine. It requires serious preparation (SSRI discontinuation is mandatory). For patients open to a spiritual or ceremonial frame, it offers a held, communal experience across multiple nights.
→ Full Guide: Ayahuasca Retreats
6. 5-MeO-DMT — The Profound Short Journey
Best for: Depression, addiction, PTSD, rapid consciousness shift Legal in US? No — international (Mexico, Jamaica, Costa Rica) Cost: Included in an ibogaine program, or $300–$1,500 on its own Sessions: 1–3
5-MeO-DMT produces one of the most intense psychedelic experiences possible — complete ego dissolution in 15–45 minutes. It is brief, overwhelming, and for many people, permanently life-altering. Emerging research supports its application for depression and addiction, particularly when combined with ibogaine in Mexico protocols.
The Bottom Line
The right choice depends on your specific situation. That’s exactly why Psychedelic Connect exists.
We’re not a directory. We’re a concierge. We ask about your full history, your goals, your medical situation, and your circumstances — then help you understand which option (or which sequence) makes the most sense for you. No charge.
(866) 435-7057 | Book a Consultation →
See also: Psychedelic Therapy Overview | Ibogaine Safety Guide
Related on this site: psychedelic therapy guide · ibogaine treatment guide · psilocybin therapy · ketamine therapy · MDMA therapy
What do people ask about The Complete Guide to Psychedelic Therapy Options in 2026?
Which option is legal in the US?
Ketamine and esketamine nationally; psilocybin in Oregon and Colorado under state programs.
Which has the best evidence?
Psilocybin and MDMA have randomised trials; ibogaine has strong observational data for opioid dependence.
How do I choose?
By condition, medical history and access. We map it with you.
Sources and further reading
- NEJM (2021): psilocybin versus escitalopram for depression — randomised, n=59
- Nature Medicine (2021): MDMA-assisted therapy for severe PTSD, phase 3 — randomised, n=90
- Nature Medicine (2024): magnesium–ibogaine therapy in veterans with traumatic brain injury — open-label, n=30, no control group
Speak with an advisor.
A confidential conversation about your situation and the options actually worth considering — from people who visit every provider they recommend.
